Cargando…
Pyoderma Gangrenosum Induced by BNT162b2 COVID-19 Vaccine in a Healthy Adult
(1) Background: Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis of unknown etiology. Coronavirus disease 2019 (COVID-19) vaccines can cause a variety of adverse cutaneous manifestations. PG associated with mRNA vaccines has not previously been described. This case study reports on the fi...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780206/ https://www.ncbi.nlm.nih.gov/pubmed/35062748 http://dx.doi.org/10.3390/vaccines10010087 |
_version_ | 1784637780138131456 |
---|---|
author | Barry, Mazin AlRajhi, Abdulaziz Aljerian, Khaldoon |
author_facet | Barry, Mazin AlRajhi, Abdulaziz Aljerian, Khaldoon |
author_sort | Barry, Mazin |
collection | PubMed |
description | (1) Background: Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis of unknown etiology. Coronavirus disease 2019 (COVID-19) vaccines can cause a variety of adverse cutaneous manifestations. PG associated with mRNA vaccines has not previously been described. This case study reports on the first patient to develop PG after receiving BNT162b2. (2) Case Presentation: An otherwise-healthy 27-year-old man developed multiple skin lesions 24 h after receiving the first dose of the messenger RNA-based Pfizer/BioNTech BNT162b2 COVID-19 vaccine. When in hospital, he developed a new painful ulcerative lesion on his right hand. Skin ulcer edge biopsy showed severe epidermal neutrophilic infiltrate with epidermal and dermal edema, underlying superficial dermal necrosis, and characteristic undermining with extensive mixed inflammatory infiltration of the dermis and abscess formation consistent with an ulcer with mixed dermal inflammation compatible with pyoderma gangrenosum. The lesion showed rapid improvement after the initiation of immunosuppressive therapy. (3) Conclusions: PG may be a rare adverse event related to the BNT162b2 vaccine, which could be more frequently encountered with the wide-scale use of mRNA vaccines. The continuous monitoring and surveillance of skin manifestations post-vaccination is essential. |
format | Online Article Text |
id | pubmed-8780206 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87802062022-01-22 Pyoderma Gangrenosum Induced by BNT162b2 COVID-19 Vaccine in a Healthy Adult Barry, Mazin AlRajhi, Abdulaziz Aljerian, Khaldoon Vaccines (Basel) Case Report (1) Background: Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis of unknown etiology. Coronavirus disease 2019 (COVID-19) vaccines can cause a variety of adverse cutaneous manifestations. PG associated with mRNA vaccines has not previously been described. This case study reports on the first patient to develop PG after receiving BNT162b2. (2) Case Presentation: An otherwise-healthy 27-year-old man developed multiple skin lesions 24 h after receiving the first dose of the messenger RNA-based Pfizer/BioNTech BNT162b2 COVID-19 vaccine. When in hospital, he developed a new painful ulcerative lesion on his right hand. Skin ulcer edge biopsy showed severe epidermal neutrophilic infiltrate with epidermal and dermal edema, underlying superficial dermal necrosis, and characteristic undermining with extensive mixed inflammatory infiltration of the dermis and abscess formation consistent with an ulcer with mixed dermal inflammation compatible with pyoderma gangrenosum. The lesion showed rapid improvement after the initiation of immunosuppressive therapy. (3) Conclusions: PG may be a rare adverse event related to the BNT162b2 vaccine, which could be more frequently encountered with the wide-scale use of mRNA vaccines. The continuous monitoring and surveillance of skin manifestations post-vaccination is essential. MDPI 2022-01-07 /pmc/articles/PMC8780206/ /pubmed/35062748 http://dx.doi.org/10.3390/vaccines10010087 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Barry, Mazin AlRajhi, Abdulaziz Aljerian, Khaldoon Pyoderma Gangrenosum Induced by BNT162b2 COVID-19 Vaccine in a Healthy Adult |
title | Pyoderma Gangrenosum Induced by BNT162b2 COVID-19 Vaccine in a Healthy Adult |
title_full | Pyoderma Gangrenosum Induced by BNT162b2 COVID-19 Vaccine in a Healthy Adult |
title_fullStr | Pyoderma Gangrenosum Induced by BNT162b2 COVID-19 Vaccine in a Healthy Adult |
title_full_unstemmed | Pyoderma Gangrenosum Induced by BNT162b2 COVID-19 Vaccine in a Healthy Adult |
title_short | Pyoderma Gangrenosum Induced by BNT162b2 COVID-19 Vaccine in a Healthy Adult |
title_sort | pyoderma gangrenosum induced by bnt162b2 covid-19 vaccine in a healthy adult |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8780206/ https://www.ncbi.nlm.nih.gov/pubmed/35062748 http://dx.doi.org/10.3390/vaccines10010087 |
work_keys_str_mv | AT barrymazin pyodermagangrenosuminducedbybnt162b2covid19vaccineinahealthyadult AT alrajhiabdulaziz pyodermagangrenosuminducedbybnt162b2covid19vaccineinahealthyadult AT aljeriankhaldoon pyodermagangrenosuminducedbybnt162b2covid19vaccineinahealthyadult |